Giménez-Arnau A M, Toubi E, Marsland A M, Maurer M
Department of Dermatology, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain.
Division of Allergy and Clinical Immunology, Bnai-Zion Medical Center, Haifa, Israel.
J Eur Acad Dermatol Venereol. 2016 Jul;30 Suppl 5:25-32. doi: 10.1111/jdv.13697.
This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to/who remain symptomatic despite H1 -antihistamine treatment, and has demonstrated good efficacy and safety in the clinical trial setting. Real-life clinical experience with omalizumab can be explored to address important practical questions relating to its use in CSU patients. Some experts have proposed that a consensus algorithm, covering various aspects to consider when using omalizumab in real-life clinical practice for the management of CSU, could answer many of these questions.
本增刊报道了2015年11月在德国柏林举行的第二届全球荨麻疹国际论坛的会议议程。奥马珠单抗被批准用于治疗12岁及以上对H1抗组胺药治疗反应不足或仍有症状的成人和青少年慢性自发性荨麻疹（CSU）患者，并且在临床试验中已证明具有良好的疗效和安全性。可以探索奥马珠单抗的实际临床经验，以解决与CSU患者使用该药相关的重要实际问题。一些专家提出，一种涵盖在CSU实际临床实践中使用奥马珠单抗时需考虑的各个方面的共识算法，可以回答其中许多问题。
